Saama and Pfizer Expand Agreement to Integrate AI-Driven Data Solutions Across R&D Portfolio
Saama , a provider of AI-based solutions that accelerate clinical development and commercialization, today announced a newly expanded, multi-year agreement with global biopharmaceutical leader Pfizer to help expedite clinical research.
- Saama , a provider of AI-based solutions that accelerate clinical development and commercialization, today announced a newly expanded, multi-year agreement with global biopharmaceutical leader Pfizer to help expedite clinical research.
- The agreement represents the expansion of a strategic relationship that began in 2020 when Saama and Pfizer entered into a partnership to automate Pfizer’s data review processes with artificial intelligence (AI).
- The result of that initial collaboration was Smart Data Quality (SDQ) , which significantly cut down the time to database lock.
- With this new agreement, Pfizer will continue to scale SDQ to help streamline and accelerate its data review processes across its broader portfolio of global studies.